Project
A phase II, open label, randomized, parallel arm study of
Automatically Closed · 2020 until 2021
Horber Daniel, Bickel Angelika, Weisshaupt Christian
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2020
End Date
2021
Financing
Industry
Study Design
Phase II
Keywords
NIS793, spartalizumab, gemcitabine, nab-paclitaxel,
mPDAC, TGFß, PD-1, Phase II
Brief description/objective
Study of efficacy and safety of NIS793 (anti-TGFbeta antibody)
with and without spartalizumab (anti-PD-1 antibody)
in combination with SOC chemotherapy in first-line metastatic
pancreatic ductal adenocarcinoma (mPDAC)